1. Home
  2. CALC vs RNXT Comparison

CALC vs RNXT Comparison

Compare CALC & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • RNXT
  • Stock Information
  • Founded
  • CALC 2011
  • RNXT 2012
  • Country
  • CALC United States
  • RNXT United States
  • Employees
  • CALC N/A
  • RNXT N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • RNXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CALC Health Care
  • RNXT Health Care
  • Exchange
  • CALC Nasdaq
  • RNXT Nasdaq
  • Market Cap
  • CALC 36.0M
  • RNXT 31.6M
  • IPO Year
  • CALC N/A
  • RNXT 2021
  • Fundamental
  • Price
  • CALC $2.61
  • RNXT $1.15
  • Analyst Decision
  • CALC Strong Buy
  • RNXT Strong Buy
  • Analyst Count
  • CALC 5
  • RNXT 1
  • Target Price
  • CALC $18.20
  • RNXT $9.00
  • AVG Volume (30 Days)
  • CALC 31.0K
  • RNXT 195.7K
  • Earning Date
  • CALC 03-27-2025
  • RNXT 03-31-2025
  • Dividend Yield
  • CALC N/A
  • RNXT N/A
  • EPS Growth
  • CALC N/A
  • RNXT N/A
  • EPS
  • CALC N/A
  • RNXT N/A
  • Revenue
  • CALC N/A
  • RNXT N/A
  • Revenue This Year
  • CALC N/A
  • RNXT N/A
  • Revenue Next Year
  • CALC N/A
  • RNXT N/A
  • P/E Ratio
  • CALC N/A
  • RNXT N/A
  • Revenue Growth
  • CALC N/A
  • RNXT N/A
  • 52 Week Low
  • CALC $2.05
  • RNXT $0.77
  • 52 Week High
  • CALC $6.27
  • RNXT $1.86
  • Technical
  • Relative Strength Index (RSI)
  • CALC 43.94
  • RNXT 58.08
  • Support Level
  • CALC $2.32
  • RNXT $1.32
  • Resistance Level
  • CALC $3.05
  • RNXT $1.40
  • Average True Range (ATR)
  • CALC 0.27
  • RNXT 0.11
  • MACD
  • CALC -0.01
  • RNXT 0.00
  • Stochastic Oscillator
  • CALC 43.29
  • RNXT 39.47

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: